Sign In
Buy MDWD
$13.73
-0.0300 (-0.218%)
At Close: Jun 03, 2026
MediWound: Managing A Position Ahead Of NexoBrid's PDUFA
05:16am, Sunday, 02'nd May 2021
MediWound is preparing for NexoBrid's PDUFA date that is scheduled in June of this year. If approved, NexoBrid will be entering a $200M TAM with numerous benefits over the standard-of-care.
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
01:49pm, Wednesday, 28'th Apr 2021
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
04:20pm, Monday, 26'th Apr 2021
YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and
MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
04:05pm, Wednesday, 24'th Mar 2021
Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time
MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript
12:46am, Sunday, 28'th Feb 2021
MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
09:56am, Thursday, 25'th Feb 2021
MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
06:30am, Monday, 22'nd Feb 2021
Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
01:42pm, Thursday, 18'th Feb 2021
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
04:05pm, Tuesday, 16'th Feb 2021
YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wou
MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
04:15pm, Wednesday, 10'th Feb 2021
YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wou
7 Penny Stocks That Actually Have Buy Ratings
01:22pm, Wednesday, 03'rd Feb 2021
Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
MediWound Provides Progress Update on Its EscharEx Clinical Development Program
07:00am, Monday, 11'th Jan 2021
Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients
MediWound to Participate in Upcoming Investor Conferences in January
07:00am, Tuesday, 05'th Jan 2021
YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wou
MediWound: A Collectable Investment Worthy Of A Long-Term Hold
01:03pm, Tuesday, 22'nd Dec 2020
MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent
07:30am, Monday, 21'st Dec 2020
Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021
